Abstract
Osteoarthritis is a common disease in humans, which is caused by progressive degradation of articular cartilage and imbalance of extracellular matrix turnover. It usually causes pain and malfunction of the affected joints, and the incidence of this disease increases with aging. Classical treatment for osteoarthritis is pain alleviation and, in progressed disease, surgical operations. New surgical techniques include transplantation of autologous chondrocytes or osteochondral plugs to the lesion area. However, these techniques have the problem of limited cell and tissue sources available for transplantation. Therefore, cartilage engineering and use of mesenchymal stem cells have raised a lot of interest as therapeutic approaches. Various strategies are being tested for their ability to provide tissue constructs that could be used as a replacement for the damaged cartilage. Growth factors, cytokines and mechanical forces are known to direct chondrogenesis and the maintenance of chondrocytic phenotype, although the cellular signaling events involved are often poorly known. Yet, understanding of the signal transduction mechanisms involved in chondrogenesis and cartilage tissue engineering will be very important, especially to learn how to guide stem cells into the desired differentiation path. This review aims to summarize the known signal transduction pathways involved with osteoarthritis, cartilage mechanobiology and differentiation of mesenchymal stem cells to chondrocytes.
Keywords: Osteoarthritis, articular cartilage, tissue engineering, signal transduction
Current Signal Transduction Therapy
Title: Cellular Signaling in Cartilage Tissue Engineering
Volume: 2 Issue: 1
Author(s): Mikko J. Lammi
Affiliation:
Keywords: Osteoarthritis, articular cartilage, tissue engineering, signal transduction
Abstract: Osteoarthritis is a common disease in humans, which is caused by progressive degradation of articular cartilage and imbalance of extracellular matrix turnover. It usually causes pain and malfunction of the affected joints, and the incidence of this disease increases with aging. Classical treatment for osteoarthritis is pain alleviation and, in progressed disease, surgical operations. New surgical techniques include transplantation of autologous chondrocytes or osteochondral plugs to the lesion area. However, these techniques have the problem of limited cell and tissue sources available for transplantation. Therefore, cartilage engineering and use of mesenchymal stem cells have raised a lot of interest as therapeutic approaches. Various strategies are being tested for their ability to provide tissue constructs that could be used as a replacement for the damaged cartilage. Growth factors, cytokines and mechanical forces are known to direct chondrogenesis and the maintenance of chondrocytic phenotype, although the cellular signaling events involved are often poorly known. Yet, understanding of the signal transduction mechanisms involved in chondrogenesis and cartilage tissue engineering will be very important, especially to learn how to guide stem cells into the desired differentiation path. This review aims to summarize the known signal transduction pathways involved with osteoarthritis, cartilage mechanobiology and differentiation of mesenchymal stem cells to chondrocytes.
Export Options
About this article
Cite this article as:
Lammi J. Mikko, Cellular Signaling in Cartilage Tissue Engineering, Current Signal Transduction Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157436207779317155
DOI https://dx.doi.org/10.2174/157436207779317155 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Snake Venom Phospholipases A2: A New Class of Antitumor Agents
Protein & Peptide Letters Poly-Electrolyte Complex: A Novel System for Biomedical Applications and Recent Patents
Recent Patents on Nanotechnology Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Inflammatory Signaling in Cartilage: MAPK and NF-κ B Pathways in Chondrocytes and the Use of Inhibitors for Research into Pathogenesis and Therapy of Osteoarthritis
Current Drug Targets Current Concepts on the Management of Chordoma
Current Drug Therapy MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells
Current Cancer Drug Targets A Review of the Current Role of Proton Therapy in Modern Oncology
Current Drug Therapy Recent Applications of Artificial Intelligence in Early Cancer Detection
Current Medicinal Chemistry Alginate Bead-Encapsulated PEDF Induces Ectopic Bone Formation In Vivo in the Absence of Co-Administered Mesenchymal Stem Cells
Current Drug Targets The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Association of GRP78, HIF-1α and BAG3 Expression with the Severity of Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry